Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial

Sunil V. Badve1,2,12*, Lei Zhang1,3, Jeff S. Coombes4, Elaine M. Pascoe1, Alan Cass1,5, Philip Clarke6, Paolo Ferrari7, Stephen P. McDonald8, Alicia T. Morrish1, Eugenie Pedagogos9, Vlado Perkovic1,10, Donna Reidlinger1, Anish Scaria1,11, Rowan Walker11, Liza A. Vergara1, Carmel M. Hawley1,2, David W. Johnson1,2 and on behalf of the HERO Study Collaborative Group

Abstract

Background: Erythropoiesis stimulating agent (ESA)-resistant anemia is common in chronic kidney disease (CKD).
Objectives: To evaluate the determinants of severity of ESA resistance in patients with CKD and primary ESA-resistance.
Design: Secondary analysis of a randomized controlled trial (the Handling Erythropoietin Resistance with Oxpentifylline, HERO)
Setting and patients: 53 adult patients with CKD stage 4 or 5 and primary ESA-resistant anemia (hemoglobin ≤120 g/L, ESA resistance index [ERI] ≥ 1.0 IU/kg/week/gHb for erythropoietin or ≥0.005 μg/kg/week/gHb for darbepoeitin, no cause for ESA-resistance identified).
Measurements: Iron studies, parathyroid hormone, albumin, liver enzymes, phosphate or markers of oxidative stress and inflammation.
Methods: Participants were divided into tertiles of ERI. Multinomial logistic regression was used to analyse the determinants of ERI tertiles.
Results: All patients, except one, were receiving dialysis for end-stage kidney disease. The mean ± SD ERI values in the low (n = 18), medium (n = 18) and high (n = 17) ERI tertiles were 1.4 ± 0.3, 2.3 ± 0.2 and 3.5 ± 0.8 IU/kg/week/gHb, respectively (P < 0.001). There were no significant differences observed in age, gender, ethnicity, cause of kidney disease, diabetes, iron studies, parathyroid hormone, albumin, liver enzymes, phosphate or markers of oxidative stress and inflammation between the ERI tertiles. The median [inter-quartile range] serum alkaline phosphatase concentrations in the low, medium and high ERI tertiles were 89 [64,121], 99 [76,134 and 148 [87,175] U/L, respectively (P = 0.054). There was a weak but statistically significant association between ERI and serum alkaline phosphatase (R2 = 0.06, P = 0.03). Using multinomial logistic regression, the risk of being in the high ERI tertile relative to the low ERI tertile increased with increasing serum alkaline phosphatase levels (P = 0.02). No other variables were significantly associated with ERI.
(Continued on next page)
Limitations: Small sample size; bone-specific alkaline phosphatase, other markers of bone turnover and bone biopsies not evaluated.

Conclusions: Serum alkaline phosphatase was associated with severity of ESA resistance in ESA-resistant patients with CKD. Large prospective studies are required to confirm this association. (Trial registration: Australian New Zealand Clinical Trials Registry 12608000199314)

Keywords: Erythropoiesis stimulating agents, Anemia, Chronic kidney disease, Alkaline phosphatase, Biological marker, Risk factors, Randomized controlled trial

Résumé

Contexte: L’anémie résistante à l’agent stimulant l’érythropoïèse (ASE) est courante chez les patients atteints d’insuffisance rénale chronique (IRC).

Objectifs: Évaluer les déterminants de la gravité de la résistance à l’ASE chez les patients atteints d’IRC et de la résistance primaire à l’ASE.

Type d’étude: Analyse secondaire d’un essai clinique randomisé (le Handling Erythropoietin Resistance with Oxpentifylline, HERO)

Contexte et participants: 53 patients adultes atteints d’IRC de stade 4 ou 5, de même que d’anémie résistante à l’ASE (hémoglobine ≤120 g/L, indice de résistance à l’ASE [IRA] ≥1,0 IU/kg/semaine/gHb pour l’érythropoïétine ou ≥0,005 μg/kg/semaine/gHb pour la darbépoétine, aucune cause justifiant la résistance à l’ASE).

Mesures: Mesure des taux de fer, de la parathormone, de l’albumine, de l’enzyme hépatique, du phosphate ou des marqueurs de stress oxydatif et d’inflammation.

Méthodes: Les participants étaient divisés en tertiers d’IRA. La méthode de régression logistique multinominale a été utilisée pour analyser les déterminants des tertiers d’IRA.

Résultats: Tous les patients, sauf un, recevaient une dialyse pour l’IRT. La moyenne ± ET des valeurs d’IRA des tertiers inférieur (n = 18), intermédiaire (n = 18) et supérieur (n = 17) étaient respectivement de 1,4 ± 0,3, de 2,3 ± 0,2 et de 3,5 ± 0,8 IU/kg/semaine/gHb (P < 0,001). On n’a observé aucune différence importante en fonction de l’âge, du sexe, de l’ethnicité, de la cause de l’insuffisance rénale, du diabète, des taux de fer, de la parathormone, de l’albumine, de l’enzyme hépatique, du phosphate ou des marqueurs de stress oxydatif et d’inflammation entre les tertiers d’IRA. La médiane [écart interquartile] des concentrations de phosphatase alcaline sérique des tertiers d’IRA inférieur, intermédiaire et supérieur étaient respectivement de 89 [64,121], de 99 [76,134] et de 148 [87,175] U/L (P = 0,054). Bien que statistiquement significative, la relation était plutôt faible entre l’IRA et la phosphatase alcaline sérique (R² = 0,06; P = 0,03). Selon la méthode de régression logistique multinominale, les chances de se retrouver dans le tertier d’IRA supérieur, par opposition au tertier d’IRA inférieur, augmentait avec des taux élevés de phosphatase alcaline sérique (P = 0,02). On n’a observé aucune association forte entre une autre variable et l’IRA.

Conclusion: La phosphatase alcaline sérique a été associée à une forte résistance à l’ASE chez les patients résistants à l’ASE atteints d’IRC. Des études prospectives à grande échelle sont nécessaires afin de confirmer cette association. (Enregistrement de l’essai clinique: Australian New Zealand Clinical Trials Registry 12608000199314)
Short section
What was known before
Increased serum alkaline phosphatase is associated with decreased responsiveness to erythropoiesis stimulating agents in patients with end-stage kidney disease.

What this study adds
Serum alkaline phosphatase is associated with severity of resistance to erythropoiesis stimulating agents in patients with chronic kidney disease with no identifiable causes for resistance to erythropoiesis stimulating agents.

Background
Since the introduction of erythropoiesis stimulating agents (ESA), there have been substantial reductions in the blood transfusion requirements of patients suffering from chronic kidney disease (CKD) [1]. Unfortunately, 7–14 % of all patients with end-stage kidney disease (ESKD) show a suboptimal hematologic response to ESA (Hb concentration <100 g/L) [2–4]. There are several known causes of suboptimal response to ESA. These include: female gender; [5–8] old age; [7] diabetes mellitus; [9] cardiovascular disease; [5] lower body mass index; [10] malnutrition; [5, 7, 8, 10, 11] inflammation; [5, 9–14] deficiencies of iron, [7, 8, 10, 14, 15] vitamin B12, [16] folate [17] or vitamin D; [18] hyperphosphatemia; [19] hyperparathyroidism; [13, 15] elevated levels of serum alkaline phosphatase; [15] inadequate dialysis; [8] infection; [7, 20, 21] malignancy; [7] use of ACE inhibitors or angiotensin receptor blockers; [13, 22] presence of a failed kidney transplant; [23] and anterythropoietin antibodies [24]. However, after excluding these conditions, a significant proportion of patients exhibit primary ESA-resistant anemia. The incidence and factors responsible for primary resistance to ESA are unknown.

ESA treatment targeting hemoglobin levels above 130 g/L in people with CKD is associated with deleterious [25] or neutral [26] impacts on survival and increased risks of stroke, vascular access thrombosis and hypertension without any reduction in cardiovascular events [25, 26]. However, recently published studies have demonstrated that poor response to ESA treatment, rather than achieved high hemoglobin, is associated with the observed adverse outcomes in CKD [2, 14, 27–30]. Unfortunately, there are no established therapies for primary ESA-resistant anemia [31]. The Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial evaluated the effect of pentoxifylline on erythropoiesis resistance index (ERI) in patients with advanced CKD and primary ESA-hyporesponsive anemia [32]. We conducted a post-hoc analysis of the HERO Study to evaluate the determinants of severity of ESA resistance.

Methods
Details of the HERO Study protocol and population are described elsewhere [32, 33]. In brief, the HERO Study (registration number Australian New Zealand Clinical Trials Registry 1260800199314) was a multi-centre, double-blind, randomized placebo-controlled trial to study the effect of pentoxifylline on ERI. The study was approved by ethics committees at all participating centres. All patients provided written informed consent prior to trial participation and the trial was conducted in accordance with the principles of the International Conference on Harmonisation Good Clinical Practice Guideline.

Between June 2009 and December 2011, the study enrolled 53 adult patients with stages 4 or 5 CKD (receiving dialysis treatment or estimated GFR <30 ml/min/1.73 m2) and ESA-resistant anemia on a stable dose of either erythropoietin or darbepoetin for at least 8 weeks. ESA-resistant anemia was defined as hemoglobin concentration ≤120 g/L and ERI ≥1.0 IU/kg/week per g/L for erythropoietin and ≥0.005 µg/kg/week per g/L for darbepoetin. ERI was calculated as weight-adjusted weekly dose of ESA divided by hemoglobin concentration, (expressed as IU/kg/week per g/L). ERI for darbepoetin-treated patients was converted to an erythropoietin-equivalent value using a dose conversion factor of 200:1.

Patients with an identifiable cause for their ESA hyporesponsiveness (such as iron deficiency, bleeding, inadequate dialysis, parathyroid hormone >100 pmol/L, malignancy or hematologic disorder, major surgery, infection, acute myocardial infarction or malignancy within the last 3 months) were excluded. Participants were randomized in a 1:1 ratio to receive pentoxifylline (Trental®; Sanofi-Aventis, Sydney, Australia) 400 mg daily orally or an identical matching placebo. The randomization was performed by an adaptive allocation algorithm designed to minimize imbalance in treatment groups across three variables: study site; CKD stage (4 or 5) and ESA class (erythropoietin or darbepoetin) using a password-protected web-based system. The follow up period was 4 months, unless a participant experienced a hemoglobin concentration <65 g/L or required a blood transfusion. The primary efficacy outcome was ERI. Secondary outcome variables were hemoglobin concentration, ESA dose, rate of blood transfusions, adverse events, quality of life and cost-effectiveness analysis. Of the 53 participants, plasma samples for four oxidative stress biomarkers (total F2-isoprostanes, protein carbonyls, glutathione peroxidase [GPX] and superoxide dismutase [SOD] activities) were available in 41 participants.

Statistical analysis
This post-hoc analysis included only the baseline data from the main HERO Study and oxidative stress sub-study. Results were expressed as frequencies (percentages) for categorical variables, mean ± standard deviation for continuous normally distributed variables and median [interquartile range] for continuous non-normally distributed variables. Participants were divided into
Table 1 Baseline characteristics according to tertiles of ERI

| Variable                        | ERI tertile | P      |
|---------------------------------|-------------|--------|
|                                | Low (n=18)  | Medium (n=18) | High (n=17) |        |
| n                               |             |         |            |        |
| ERI (IU/kg/wk/gHb)              | 1.4 ± 0.3   | 2.3 ± 0.2 | 3.5 ± 0.8  | <0.001 |
| ESA dose (IU/kg/wk)             | 153 ± 37    | 233 ± 25 | 362 ± 79   | <0.001 |
| Type of ESA                     |             |         |            | 0.8    |
| Erythropoietin                  |             |         |            |        |
| Darbepoetin                     | 7 (39 %)    | 6 (33 %) | 5 (29 %)   |        |
| Hemoglobin (g/L)                | 111 ± 8     | 102 ± 13 | 105 ± 10   | 0.05   |
| Men                             | 10 (56 %)   | 8 (44 %) | 6 (35 %)   | 0.5    |
| Age (years)                     | 67.7 ± 13   | 58.4 ± 17.6 | 60.5 ± 15.5 | 0.2 |
| Ethnicity                       |             |         |            | 0.4    |
| Caucasian                       | 14 (78 %)   | 14 (78 %) | 15 (88 %)  |        |
| Aboriginal or Torres Strait Islander | 0         | 1 (6 %)  | 0            |    |
| Maori/Pacific Islander          | 0           | 1 (6 %)  | 0            |    |
| Asian                           | 3 (17 %)    | 2 (11 %) | 0            |    |
| Other                           | 1 (6 %)     | 0        | 2 (12 %)    |        |
| Cause of kidney disease<sup>b</sup> |             |         |            | 0.9   |
| Diabetes                        | 8 (44 %)    | 8 (47 %) | 5 (29 %)    |        |
| Glomerulonephritis              | 2 (11 %)    | 1 (6 %)  | 4 (24 %)    |        |
| Analgesic nephropathy           | 0           | 1 (6 %)  | 0            |        |
| Polycystic kidney disease       | 1 (6 %)     | 1 (6 %)  | 1 (6 %)     |        |
| Reflux nephropathy              | 1 (6 %)     | 1 (6 %)  | 1 (6 %)     |        |
| Renovascular disease            | 0           | 1 (6 %)  | 1 (6 %)     |        |
| Others                          | 6 (33)      | 4 (24 %) | 5 (29 %)    |        |
| Type of dialysis<sup>b</sup>    |             |         |            | 0.4   |
| Hemodialysis                    | 17 (94 %)   | 16 (94 %) | 17 (100 %)  |        |
| Peritoneal dialysis             | 1 (6 %)     | 0        | 0            |        |
| Pre-dialysis                    | 0           | 1 (6 %)  | 0            |        |
| Diabetes mellitus<sup>c</sup>   | 10 (67 %)   | 9 (82 %) | 6 (46 %)    | 0.2    |
| Ischemic heart disease<sup>c</sup> | 7 (47 %) | 4 (36 %) | 7 (54 %)    | 0.7   |
| Congestive heart failure<sup>c</sup> | 2 (13 %) | 1 (9 %) | 5 (38 %)    | 0.1   |
| Cerebrovascular disease<sup>c</sup> | 1 (7 %) | 0        | 3 (23 %)    | 0.2   |
| Peripheral vascular disease<sup>c</sup> | 2 (13 %) | 4 (36 %) | 4 (31 %)    | 0.4   |
| Smoking status<sup>b</sup>      |             |         |            | 0.3   |
| Never                           | 9 (50 %)    | 5 (29 %) | 9 (53 %)    |        |
| Former                          | 8 (44 %)    | 11 (65 %) | 5 (29 %)    |        |
| Current                         | 1 (6 %)     | 1 (6 %)  | 3 (18 %)    |        |
| Body mass index (kg/m<sup>2</sup>) | 28.6 ± 4.8 | 30.4 ± 7.4 | 29.2 ± 7.6 | 0.7   |
| Body mass index category        |             |         |            | 0.3    |
| Underweight (<18.5 kg/m<sup>2</sup>) | 0         | 0        | 0           |        |
| Healthy weight (18.5 – 24.9 kg/m<sup>2</sup>) | 5 (28 %) | 4 (22 %) | 6 (35 %)    |        |
| Overweight (25 – 29.9 kg/m<sup>2</sup>) | 9 (50 %) | 6 (33 %) | 3 (18 %)    |        |
| Obese (>30 kg/m<sup>2</sup>)    | 4 (22 %)    | 8 (44 %) | 8 (47 %)    |        |
| Hematocrit (%)                  | 34 ± 3      | 32 ± 5   | 32 ± 3      | 0.7    |
Table 1 Baseline characteristics according to tertiles of ERI (Continued)

| Characteristic                        | ERI < 0.05 (n=42) | ERI 0.05-0.1 (n=47) | ERI > 0.1 (n=47) |
|---------------------------------------|-------------------|---------------------|------------------|
| Mean cellular volume (fL)             | 94.4 ± 7.8        | 95.3 ± 6.6          | 94.3 ± 5.9       |
| Reticulocyte count (10^9/L)           | 57 ± 21           | 74 ± 38             | 64 ± 31          |
| Total white cell count (x 10^9/L)     | 6.8 ± 2           | 64.2 ± 2.1          | 66.6 ± 1.5       |
| Platelet count (x 10^9/L)             | 207 [164, 286]    | 188 [167, 207]      | 197 [164, 274]   |
| Ferritin (μg/L)                       | 413 [241, 958]    | 527 [298, 647]      | 487 [315, 594]   |
| Transferrin saturation (%)            | 26 [20, 30]       | 22 [17, 30]         | 23 [22, 29]      |
| Serum bicarbonate (mmol/L)            | 23.3 ± 4          | 22.6 ± 3            | 23.6 ± 3         |
| Albumin (g/L)                         | 36 ± 4            | 35 ± 4              | 35 ± 5           |
| Serum alkaline phosphatase (U/L)      | 89 [64, 121]      | 99 [76, 134]        | 148 [87, 175]    |
| Gamma-glutamyltransferase (U/L)       | 23 [16, 40]       | 25 [17, 60]         | 32 [16, 57]      |
| Alanine transaminase (U/L)            | 16 [11, 19]       | 15 [9, 22]          | 10 [8, 19]       |
| Aspartate transaminase (U/L)          | 18 [13, 22]       | 17 [12, 23]         | 14 [10, 17]      |
| Lactate dehydrogenase (U/L)           | 224 ± 57          | 224 ± 85            | 265 ± 63         |
| Albumin-corrected calcium (mmol/L)    | 2.3 ± 0.3         | 2.3 ± 0.1           | 2.2 ± 0.2        |
| Phosphate (mmol/L)                    | 1.7 ± 0.5         | 1.7 ± 0.5           | 1.7 ± 0.5        |
| Parathyroid hormone (pmol/L)          | 17 [9, 35]        | 33 [17, 42]         | 32 [16, 65]      |
| C-reactive protein (mg/L)             | 3 [2, 21]         | 12 [4, 28]          | 15 [7, 31]       |
| **Oxidative stress substudy**         |                   |                     |                  |
| n                                     | 14                | 13                  | 14               |
| Total F2-isoprostanes (pg/mL)         | 133 [87, 213]     | 143 [128, 200]      | 112 [67, 173]    |
| Glutathione peroxidase activity (U/L) | 177 [13]          | 181 [10]            | 174 [14]         |
| Superoxide dismutase activity (U/mL)  | 1.97 [1.41, 2.6]  | 2.01 [1.32, 2.44]   | 2.22 [1.71, 2.71]|
| Protein carbonyls (nmol/mg)           | 0.56 [0.46, 0.6]  | 0.55 [0.46, 0.74]   | 0.55 [0.51, 0.69]|

* Patients on darbepoetin were converted to an erythropoietin-equivalent dose using a conversion factor of 200:1
*1 Missing data from medium ERI tertile
*2 Missing data- 3, 7 and 4 values missing from low, medium and high ERI tertiles, respectively
*3 Median [IQR]
*4 to convert phosphate level from mmol/L to mg/dL multiply by 3.1
*5 to convert parathyroid level from pmol/L to pg/mL multiply by 9.4

Fig. 1 Scatterplot showing the association between serum alkaline phosphatase and ESA resistance index
tertiles of ERI (low, medium and high ERI). Differences between groups of patients were analysed by $\chi^2$ test for categorical data; one-way analysis of variance for continuous variables if data were normally distributed and Kruskal–Wallis test for non-normally distributed data. Simple linear regression was used to analyze the association between ERI and other variables. Non-normally distributed variables were appropriately transformed to improve normality of distribution. Associations between ERI and the following variables were analysed in linear regression models: gender, ethnicity, diabetes mellitus, cause of kidney disease, smoking status, ischemic heart disease, congestive heart failure, and body mass index category, age, reticulocyte count, total white cell count, ferritin, transferrin saturation, albumin, alkaline phosphatase, gamma-glutamyltransferase, alanine transaminase, aspartate transaminase, lactate dehydrogenase, albumin-corrected calcium, phosphate, parathyroid hormone, C-reactive protein, total F2-isoprostanes, protein carbonyls, GPX and SOD activities. Predictors of high ERI tertile versus low and medium ERI tertiles were determined by univariate multinomial logistic regression models. The same above mentioned variables were used in these models. Analysis was conducted using Stata/SE (version 11.2, Stata Corp., College Station, TX, USA).

Results
Patient characteristics
Baseline characteristics of the study population according to ERI tertiles are described in Table 1. The mean ERI values in the low, medium and high ERI tertiles were $1.4 \pm 0.3$, $2.3 \pm 0.2$ and $3.5 \pm 0.8$ IU/kg/week/gHb, respectively. Increasing ERI was associated with both higher ESA dose and lower hemoglobin level (Table 1). Serum alkaline phosphatase concentrations also increased with increasing ERI. Median [IQR] serum alkaline phosphatase levels in the low, medium and high ERI tertiles were 89 [64, 121], 99 [76, 134] and 148 [87, 175] U/L, respectively ($P = 0.054$, Table 1). There were no statistically significant differences observed between the ERI tertiles with respect to age, gender, ethnic origin, cause of kidney disease, smoking status, dialysis modality, comorbidities, body mass index, other laboratory values or oxidative stress markers (Table 1).

Determinants of ESA resistance index
Using simple linear regression, there was a weak but statistically significant association between ERI and alkaline phosphatase ($R^2 = 0.06, P = 0.03$) (Fig. 1). On multinomial logistic regression, the risk of being in the high ERI tertile relative to the low ERI tertile increased with increasing alkaline phosphatase levels ($P = 0.02$). No other variables were significantly associated with ERI on univariate analysis (Tables 2 and 3).

### Table 2 Associations between participant characteristics and ERI by simple linear regression

| Variable                                      | R^2   | P value |
|----------------------------------------------|-------|---------|
| Women (Reference men)                        | −0.02 | 0.8     |
| Non-Caucasians (Reference Caucasians)        | −0.02 | 0.7     |
| Diabetes mellitus (Reference non-diabetics)  | 0.01  | 0.2     |
| Cause of kidney disease                      | −0.03 | 0.6     |
| Smoking status                               | −0.02 | 0.6     |
| Body mass index                              | 0.02  | 0.2     |
| Ischemic heart disease                       | −0.01 | 0.4     |
| Congestive heart failure                     | 0.02  | 0.2     |
| Age                                          | 0.01  | 0.2     |
| Reticulocyte count                           | −0.01 | 0.6     |
| Total white cell count                       | −0.02 | 0.8     |
| Ferritin^a                                   | −0.01 | 0.5     |
| Transferrin saturation^b                     | −0.01 | 0.6     |
| Albumin                                      | 0.001 | 0.3     |
| Alkaline phosphatase^c                       | 0.06  | 0.03    |
| Gamma-glutamyltransferase^d                  | 0.01  | 0.2     |
| Alanine transaminase^e                       | 0.02  | 0.1     |
| Aspartate transaminase^f                     | 0.04  | 0.09    |
| Lactate dehydrogenase^g                      | 0.07  | 0.05    |
| Albumin-corrected calcium                    | 0.05  | 0.06    |
| Phosphate                                    | −0.02 | 0.9     |
| Parathyroid hormone^h                        | 0.04  | 0.09    |
| C-reactive protein                           | 0.03  | 0.09    |
| Total F2-isoprostanes^h                      | −0.01 | 0.5     |
| Glutathione peroxidise activity^i            | −0.004| 0.9     |
| Superoxide dismutase activity^o              | −0.01 | 0.5     |
| Protein carbonyls^o                          | −0.03 | 0.9     |

*The following non-normally distributed variables were transformed to normality of distribution:  
^a reciprocal of square root  
^b log-transformed  
^c reciprocal of square root  
^d power of 3  
^e reciprocal

Discussion
This secondary analysis of the HERO Study showed that serum alkaline phosphatase was associated with severity of ESA resistance in a selected group of patients with advanced CKD who did not have any identifiable cause of ESA-resistant anemia. No other factors were found to be associated with severity of ESA resistance.

In a study involving 38,328 ESKD patients receiving hemodialysis, Kalantar-Zadeh and colleagues reported a positive association between serum alkaline phosphatase level and ESA hyporesponsiveness [15]. Importantly, this association persisted even after adjusting for other known causes of anemia, such as older age, gender, diabetes
Table 3: Associations between participant characteristics and ERI by univariate multinomial logistic regression

| Variable                                             | Coefficient | 95% confidence intervals      | P value |
|------------------------------------------------------|-------------|-------------------------------|---------|
| Women (Reference men)                                | −0.83       | −2.19 to 0.53                 | 0.2     |
| Non-Caucasians (Reference Caucasians)                | 0.76        | −1.08 to 2.61                 | 0.4     |
| Diabetes mellitus (Reference non-diabetics)          | 0.85        | −0.68 to 2.38                 | 0.3     |
| Cause of kidney disease                              |             |                               |         |
| Diabetes Reference                                   |             |                               |         |
| Glomerulonephritis                                   | −1.16       | −3.19 to 0.87                 | 0.3     |
| Analgesic nephropathy                                | NR          | NR                            | NR      |
| Polycystic kidney disease                            | −0.47       | −3.46 to 2.52                 | 0.8     |
| Reflux nephropathy                                   | −0.47       | −3.46 to 2.52                 | 0.8     |
| Renovascular disease                                 | NR          | NR                            | NR      |
| Others                                               | −0.29       | −1.92 to 1.34                 | 0.7     |
| Smoking status                                        |             |                               |         |
| Never Reference                                      |             |                               |         |
| Former                                               | 0.47        | −0.98 to 1.92                 | 0.5     |
| Current                                              | −1.10       | −3.54 to 1.35                 | 0.4     |
| Body mass index category                             |             |                               |         |
| Healthy weight Reference                             |             |                               |         |
| Overweight                                           | 1.28        | −0.48 to 3.05                 | 0.2     |
| Obese                                                | −0.51       | −2.20 to 1.18                 | 0.6     |
| Ischemic heart disease                               | −0.28       | −1.78 to 1.20                 | 0.7     |
| Congestive heart failure                             | −1.40       | −3.26 to 0.46                 | 0.1     |
| Age                                                  | 0.03        | −0.01 to 0.08                 | 0.2     |
| Reticulocyte count                                   | −0.01       | −0.03 to 0.02                 | 0.5     |
| Total white cell count                               | 0.03        | −0.33 to 0.40                 | 0.9     |
| Ferritin                                             | 0.01        | −0.09 to 0.11                 | 0.8     |
| Transferrin saturation                               | 0.05        | −2.29 to 2.39                 | 0.9     |
| Albumin                                              | 0.06        | −0.09 to 0.21                 | 0.4     |
| Alkaline phosphatase                                 | 44.01       | 7.63 to 80.40                 | 0.002   |
| Gamma-glutamyltransferase                            | −0.65       | −1.60 to 0.30                 | 0.2     |
| Alanine transaminase                                 | −7.42       | −16.80 to 1.96                | 0.1     |
| Aspartate transaminase                               | −8.50       | −20.62 to 3.62                | 0.2     |
| Lactate dehydrogenase                                | −2.18       | −5.06 to 0.69                 | 0.1     |
| Albumin-corrected calcium                            | 3.46        | −0.60 to 7.51                 | 0.09    |
| Phosphate                                            | −0.01       | −1.31 to 1.29                 | 0.9     |
| Parathyroid hormone                                  | −0.25       | −0.55 to 0.05                 | 0.1     |
| C-reactive protein                                   | −0.03       | −0.08 to 0.01                 | 0.2     |
| Total F2-isoprostanes                                | 0.36        | −0.69 to 1.42                 | 0.5     |
| Glutathione peroxidase activity^d                    | NR          | NR                            | NR      |
| Superoxide dismutase activity^e^                     | 1.49        | −1.91 to 4.90                 | 0.4     |
| Protein carbonyls                                     | 0.24        | −1.26 to 1.74                 | 0.8     |

NR: Estimates could not be obtained due to small number of patients

The following non-normally distributed variables were transformed to normality of distribution:

^square root
^log-transformed
^reciprocal of square root
^power of 3
^reciprocal
mellitus, body mass index, iron studies, markers of bone disease, parathyroid level and markers of malnutrition. Other investigators have reported improvement in hemoglobin concentration and reductions in the serum alkaline phosphatase level and ESA dose after parathyroidectomy [34, 35]. Previous studies have also demonstrated that alkaline phosphatase is associated with mortality in ESKD patients receiving dialysis [36–39] and pre-dialysis patients with CKD [40–43]. A major difference between the present study and previous investigations is that the HERO study excluded patients with any identifiable cause of ESA-resistant anemia, such as deficiencies of iron or vitamin B12 or folate, bleeding, inadequate dialysis, severe hyperparathyroidism (PTH >100 pmol/L), malignancy or hematologic disorder, major surgery, infection, acute myocardial infarction or malignancy within the last 3 months. Indeed, this is the first study describing the determinants of severity of ESA resistance in patients with primary ESA-resistance, as previous studies included patients with no ESA resistance as well as those with known secondary causes of ESA resistance.

Approximately 31–37% of ESKD patients receiving dialysis have raised levels of serum alkaline phosphatase [36, 44]. Serum alkaline phosphatase in the dialysis population is strongly associated with serum concentrations of parathyroid hormone and aspartate transaminase [36]. Although bone and liver alkaline phosphatase are found in equal proportions in healthy adults, 28% of ESKD patients on haemodialysis with increased bone alkaline phosphatase have normal alkaline phosphatase levels [44]. In a study involving 800 ESKD patients receiving haemodialysis, Drechsler and colleagues showed a strong association between bone alkaline phosphatase and all-cause and cardiovascular mortality [37].

The most likely reason for the observed association between alkaline phosphatase and severity of ESA resistance in the present study is increased bone turnover and marrow fibrosis, since the median serum PTH levels in the middle and high ERI tertiles were 33 and 32 pmol/L, respectively compared with 17 pmol/L in the low ERI tertile [45]. In the current study, there was no statistically significant association observed between parathyroid hormone and primary ESA-resistance. It is important to note that the HERO Study excluded patients with a serum parathyroid hormone level greater than 100 pmol/L, such that included patients only had mild-to-moderate secondary hyperparathyroidism. Nevertheless, even at these relatively modest elevations of serum PTH, alkaline phosphatase was still significantly associated with ESA resistance.

A strength of the study was that it involved patients from multiple centers across two countries, enhancing the internal and external validity of the findings. On the other hand, the study was limited by a relatively small sample size, such that it is possible that some associations with severity of ESA resistance were not able to be ascertained due to a type 2 statistical error. Moreover, as multiple variables were evaluated in this study, the observed association between alkaline phosphatase and severity of ESA resistance could have been due to a type 1 statistical error. Bone-specific alkaline phosphatase, other markers of bone turnover and bone biopsies were not evaluated, thereby limiting more detailed exploration of the potential mechanisms underpinning the association between serum alkaline phosphatase and severity of ESA resistance. Since the HERO study included a highly selected group of patients with no identifiable cause of ESA-resistant anemia, the findings of this study may not be generalizable to patients with a known cause of ESA hyporesponsiveness. This finding is hypothesis generating and needs to be confirmed by other studies.

**Conclusions**

Alkaline phosphatase was associated with severity of ESA resistance in patients with advanced CKD and no apparent secondary cause of ESA-resistance. Larger prospective studies are required to confirm this association.

**Abbreviations**

ACE: Angiotensin converting enzyme; CKD: Chronic kidney disease; ERI: Erythropoiesis resistance index; ESA: Erythropoiesis stimulating agents; ESKD: End-stage kidney disease; GPX: Glutathione peroxidase; HERO: The Handling Erythropoietin Resistance with Oxpentifylline trial; IQR: Interquartile range; PTH: Parathyroid hormone; SOD: Superoxide dismutase.

**Competing interests**

DWJ has previously received consultancy fees from Sanofi-Aventis. He has also previously received consultancy fees, speakers’ honoraria, research grants and travel sponsorships from Amgen, Roche and Janssen-Cilag. He was the recipient of a Roche Foundation for Anemia Research (RoFAR) Grant, which partly funded the HERO trial, and a Queensland Government Health Research Fellowship. CMH has previously received consultancy fees, speakers’ honoraria, research grants and/or travel sponsorships from Amgen, Roche and Janssen-Cilag. JC has received a speakers’ honorarium from Roche. AC has previously received consultancy fees, speakers’ honoraria and/or research grants from Amgen, Roche, Baxter, Fresenius and Merck. RW has previously received consultancy fees, speakers’ honoraria, research grants and travel sponsorships from Amgen, Roche and Janssen-Cilag and has served on Advisory Boards for Amgen, Roche and Janssen-Cilag. EP has previously received consultancy fees, speakers’ honoraria, research grants and/or travel sponsorships from Amgen, Sanofi and Roche. All other authors have no conflict of interest to declare.

**Authors’ contributions**

The HERO Study Collaborative Group comprises the Trial Management Committee (Emmanuel d’Almeida (Department of Nephrology, John Hunter Hospital, Newcastle, Australia), Rob Fassett (Department of Nephrology, Royal Brisbane and Women’s Hospital, Brisbane, Australia), Carl Kirkpatrick (Center for Medicine Use and Safety, Monash University, Melbourne, Australia), Badve et al. Canadian Journal of Kidney Health and Disease (2015) 2:33
Richard Phoon (Department of Nephrology, Westmead Hospital, Sydney, Australia), and the members of the Writing Committee.

Financial support
The HERO trial was funded by research grants from Roche Foundation for Anemia Research (RoFAr), Argen, Jansen-Cilag and the National Health and Medical Research Council of Australia. The funders had no role in study design, collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication.

Author details
1Australasian Kidney Trials Network, University of Queensland, Brisbane, Australia. 2Department of Nephrology, Princess Alexandra Hospital, Brisbane, Australia. 3Department of Nephrology, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China. 4School of Human Movement Studies, University of Queensland, Brisbane, Australia. 5Menzies School of Health Research, Darwin, Australia. 6Centre for Health Policy, Programs & Economics, University of Melbourne, Melbourne, Australia. 7Department of Nephrology, Prince of Wales Hospital, Sydney, Australia. 8Department of Nephrology and Transplantation Services, University of Adelaide at Central Northern Adelaide Renal and Transplantation Services, Adelaide, Australia. 9Department of Nephrology, Royal Melbourne Hospital, Melbourne, Australia. 10The George Institute for Global Health, Sydney, Australia. 11Department of Renal Medicine, The Alfred Hospital, Melbourne, Australia. 12Department of Nephrology, Level 2, ARTS Building, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Queensland 4102, Australia.

Received: 17 May 2015 Accepted: 29 July 2015

Published online: 18 August 2015

References
1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73–8
2. Messana JM, Chuang CC, Turenne M, Wheeler J, Turner J, Sleeman K, et al. Association of quarterly average achieved hematocrit with mortality in dialysis patients: a time-dependent comorbidity-adjusted model. Am J Kidney Dis. 2009;53(3):503–12.
3. Offthun N, Labrecque J, Lacois E, Keen M, Lazarus JM. Effects of the higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63(5):1908–14.
4. Macdougall IC, Tomson CR, Steenkamp M, Ansell D. Relative risk of death in UK haemodialysis patients in relation to achieved haemoglobin from 1999 to 2005: an observational study using UK Renal Registry data incorporating 30,040 patient-years of follow-up. Nephrol Dial Transplant. 2010;25(3):914–9.
5. de Lurdes Agostinho Cabrita A, Pinho A, Malho A, Morgado E, Falisa M, Carraques H, et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. Int Urol Nephrol. 2011;43(3):835–40.
6. Di Iorio BR, Stelloo D, De Santo NG, Cirillo M. Association of gender and age with erythropoietin resistance in hemodialysis patients: role of menstrual status. Blood Purif. 2006;22(3):423–7.
7. Lopez-Gomez JM, Portoles JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl. 2008;111:575–81.
8. Mallick S, Rafiouin A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2011;6(4):328–34.
9. Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K, Soma M. Relationship between erythropoietin responsiveness, insulin resistance, and malnutrition-inflammation-atherosclerosis (MIA) syndrome in hemodialysis patients with diabetes. Int J Antivirals. 2011;14(1):16–25.
10. Locatelli F, Andrelli S, Menni B, Maffei C, Del Vecchio L, Aterini S, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in hemodialysis patients. Nephrol Dial Transplant. 2006;21(4):991–8.
11. Gunnel J, Yeun Jr, Depner TA, Kayser GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33(1):63–72.
12. Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008;28(3):268–75.
13. Pajek J, Bucar-Pajek M, Grego K, Gucek A, Blec S, Ebert R, et al. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study. Ther Apher Dial. 2005;9(3):226–32.
14. Szczecz LA, Bamhart HK, Irving K, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74(6):791–8.
15. Kalantar-Zadeh K, Lee GH, Miller JE, Stree J, Jing J, Robertson JA, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis. 2006;53(5):823–34.
16. Zachee P, Chew SL, Daellemans R, Rins RL. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol. 1992;12(3):188–91.
17. Bamgbola OF, Kaskel F. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol. 2005;20(11):1622–9.
18. Kiss Z, Ambrus C, Almassi C, Berta K, Deak G, Horonyi P, et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. Nephron Clin Pract. 2011;1:17(4):c73–8.
19. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients? Nephrology (Carlton). 2006;11(5):394–9.
20. Muirhead N, Hoarau A, B. Occult infection and resistance of anaemia to HuEpo therapy in renal failure. Nephrol Dial Transplant. 1995;5(3):232–4.
21. Nassar GM, Fishbane S, Ayus JC. Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl. 2002;80:49–54.
22. DeLong M, Logan JL, Yong KC, Lien YH. Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on hemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant. 2005;20(3):585–90.
23. Lopez-Gomez JM, Perez-Flores J, Joffe R, Carretero D, Rodriguez-Benitez P, Villavende M, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol. 2004;15(9):2494–501.
24. Casadevall N, Natoff J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, et al. Pure red-cell aplasia and antienythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469–75.
25. Phrommintikul A, Haas S, Elsk M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007;369(9559):381–8.
26. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Secondary analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(3):23–33.
27. Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, et al. Greater epoetin alfalfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1077–83.
28. Regidor DL, Koppel JD, Kovessy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17(4):1181–91.
29. Solomon SD, Uno H, Lewis EF, Eckardt K-U, Lin J, Burdmann EA, et al. Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2010;363(12):1146–55.
30. Badve SV, Hawley CM, Johnson DW. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD? Nephrology (Carlton). 2011;16(12):144–53.
31. Badve SV, Beller EM, Cass A, Francis DP, Hawley C, Macdougall IC, et al. Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database Syst Rev. 2013;8, CD006867.
32. Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxphenyltin (HERO) trial. Am J Kidney Dis. 2015;65(1):49–57.
33. Johnson DW, Hawley CM, Rosser B, Beller E, Thompson C, Fassett RG, et al. Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrol. 2008;9:8.

34. Chow TL, Chan TT, Ho YW, Lam SH. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg. 2007;142(7):644–8.

35. Trunzo JA, McHenry CR, Schulak JA, Wilhelm SM. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery. 2008;144(6):915–9.

36. Regidor DL, Kovesdy CP, Mehrotra R, Rambod M, Jing J, McAllister CJ, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19(11):2193–203.

37. Dechler C, Verduijn M, Pilz S, Krediet RT, Dekker FW, Wanner C, et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol. 2011;6(7):1752–9.

38. Nigwekar SU, Wenger J, Thadhani R, Bhan I. Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study. Am J Kidney Dis. 2013;62(4):755–62.

39. Rhee CM, Molinar MZ, Lau WL, Ravel V, Kovesdy CP, Mehrotra R, et al. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. Perit Dial Int. 2014;34(7):732–48.

40. Beddu S, Ma X, Baird B, Cheung AK, Greene T. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(11):1805–10.

41. Kovesdy CP, Ureche V, Lu JL, Kalantar-Zadeh K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant. 2010;25(9):3003–11.

42. Taliercio JJ, Schold JD, Simon JF, Aminaghi S, Tang A, Saab G, et al. Prognostic importance of serum alkaline phosphatase in CKD stages 3–4 in a clinical population. Am J Kidney Dis. 2013;62(4):703–10.

43. Beige J, Wendt R, Giirndt M, Queck KH, Fedler R, Jehle P. Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis. BMJ Open. 2014;4(2), e004275.

44. Tibi L, Chhabra SC, Sweeting VM, Winney RJ, Smith AF. Multiple forms of alkaline phosphatase in plasma of hemodialysis patients. Clin Chem. 1991;37(6):815–20.

45. Barreto FC, Barreto DV, Moyes RM, Neves KR, Canziani ME, Draibe SA, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73(6):771–7.
Author/s:
Badve, SV; Zhang, L; Coombes, JS; Pascoe, EM; Cass, A; Clarke, P; Ferrari, P; McDonald, SP; Morrish, AT; Pedagogos, E; Perkovic, V; Reidlinger, D; Scaria, A; Walker, R; Vergara, LA; Hawley, CM; Johnson, DW; HERO Study Collaborative Group,

Title:
Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Date:
2015

Citation:
Badve, S. V., Zhang, L., Coombes, J. S., Pascoe, E. M., Cass, A., Clarke, P., Ferrari, P., McDonald, S. P., Morrish, A. T., Pedagogos, E., Perkovic, V., Reidlinger, D., Scaria, A., Walker, R., Vergara, L. A., Hawley, C. M., Johnson, D. W. & HERO Study Collaborative Group, (2015). Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.. Can J Kidney Health Dis, 2 (1), pp.33-. https://doi.org/10.1186/s40697-015-0066-5.

Persistent Link:
http://hdl.handle.net/11343/57314

File Description:
Published version

License:
CC BY